Madrigal Pharmaceuticals Inc. (MDGL)
NASDAQ: MDGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 487.72 0.00%
MDGL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $11.27B
- Forward P/E
- 50.67
- EPS (TTM)
- -$12.85
- Dividend yield
- None
- 52-week range
- 393.61 – 615.00
- Day range
- 486.77 – 502.34
- Volume / Avg
- 256.24K / 292.63K
- Beta
- —
- Shares outstanding
- 23.10M
- Next earnings
- Nov 3, 2026
52-week range
MDGL stock today
Shares of Madrigal Pharmaceuticals (MDGL) finished lower on Oct 7 at $487.72, a drop of 1.76% or $8.73 per share, versus the S&P 500's 0.22% decline. At this level, MDGL sits in the middle of its 52-week range of $393.61 to $615.00: 20.7% below the high, set on Dec 24, 2025 and 23.9% above the low. MDGL is down 16.2% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 11.8%.
Madrigal Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$12.85), so its P/E ratio is not meaningful. Madrigal Pharmaceuticals's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Madrigal Pharmaceuticals
Company profileMadrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. William J. Sibold
- Headquarters
- West Conshohocken, PA
- Employees
- 915
- IPO year
- 2007
- Website
- madrigalpharma.com
Financial highlights
Full financialsIn fiscal 2025, Madrigal Pharmaceuticals generated $958.4 million in revenue, up 432.1% from fiscal 2024, its 2nd consecutive year of revenue growth. Madrigal Pharmaceuticals reported a net loss of $288.3 million, compared with a loss of $465.9 million a year earlier. Operating margin was -31.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $958.40M | $180.13M | $0 | $0 | $0 |
| Growth | +432.05% | — | — | — | — |
| Net income | $-288.28M | $-465.89M | $-373.63M | $-295.35M | $-241.85M |
| EPS (diluted) | $-10.15 | $-17.31 | $-17.33 | $-17.23 | $-14.63 |
Analyst forecast
ForecastConsensus (19 analysts)
strong_buy
Avg. price target
$682.11+39.86%
- Strong buy 3
- Buy 15
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $1.00
- Last reported (Q2 2026)
- Jul 30, 2026
- EPS actual vs est.
- $-1.99 vs —
MDGL news
All MDGL newsMadrigal Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ELANElanco Animal Health Incorporated | 22.36 | -0.53% | $11.17B | vs MDGL |
| BMRNBioMarin Pharmaceutical Inc. | 55.20 | -1.81% | $10.69B | vs MDGL |
| RDYDr. Reddy's Laboratories Ltd | 12.27 | -1.76% | $10.22B | vs MDGL |
| CORTCorcept Therapeutics Incorporated | 119.60 | +0.03% | $12.93B | vs MDGL |
| BBIOBridgeBio Pharma Inc. | 66.50 | -0.69% | $13.00B | vs MDGL |
| PTGXProtagonist Therapeutics Inc. | 140.92 | +1.61% | $9.12B | vs MDGL |
| AXSMAxsome Therapeutics Inc. | 172.97 | -0.79% | $9.06B | vs MDGL |
| ARWRArrowhead Pharmaceuticals Inc. | 61.48 | -0.10% | $8.68B | vs MDGL |
Indexes, lists and sector
Madrigal Pharmaceuticals stock FAQ
What is Madrigal Pharmaceuticals's stock price today?
MDGL last traded at $487.72 as of Oct 7, 4:00 PM EDT, down 1.76% on the day. Prices are delayed at least 15 minutes.
Does Madrigal Pharmaceuticals pay a dividend?
No. Madrigal Pharmaceuticals does not currently pay a regular cash dividend.
When is Madrigal Pharmaceuticals's next earnings date?
Madrigal Pharmaceuticals is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $1.00.
Who is Madrigal Pharmaceuticals's CEO?
Mr. William J. Sibold is the chief executive officer of Madrigal Pharmaceuticals Inc., which has about 915 employees.
Has MDGL ever split its stock?
Yes. The most recent MDGL stock split was a 1-for-35 split on Jul 25, 2016.
What is the MDGL 52-week high?
The 52-week high for MDGL is $615.00 and the 52-week low is $393.61. The stock is currently 20.7% below its high.